Pooled Safety and Tolerability Data from Four Placebo-Controlled Teriflunomide Studies and Extensions
November 2015
in “
Multiple Sclerosis and Related Disorders
”
Studysummary This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on msard-journal.com →